Fired Whistleblower's Successful Appeal May Broaden State Protection Statutes

'PEOPLE ARE THE SAME': Myron Mehlman plans to pursue a $30 million defamation suit against Mobil if his case is upheld on its next appeal. A New Jersey appellate court has upheld and doubled a $3.5 million ruling in favor of a Mobil Oil Corp. toxicologist fired after advising a Mobil subsidiary in Japan to stop selling gasoline with hazardous levels of benzene, a carcinogen. While the company appeals the decision to the state Supreme Court, observers are speculating that the case may help whi

Written byThomas Durso
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share


'PEOPLE ARE THE SAME': Myron Mehlman plans to pursue a $30 million defamation suit against Mobil if his case is upheld on its next appeal.
A New Jersey appellate court has upheld and doubled a $3.5 million ruling in favor of a Mobil Oil Corp. toxicologist fired after advising a Mobil subsidiary in Japan to stop selling gasoline with hazardous levels of benzene, a carcinogen. While the company appeals the decision to the state Supreme Court, observers are speculating that the case may help whistleblowers enjoy greater protection from retaliation.

Myron Mehlman was dismissed from his job at a Mobil laboratory in Hopewell, N.J., almost immediately upon returning from Japan in October 1989. He sued the company under New Jersey's Conscientious Employee Protection Act (CEPA), and a state Superior Court jury awarded him nearly $3.5 million in compensatory damages and $3.5 million in punitive damages (F. Hoke, The Scientist, Aug. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies